<DOC>
	<DOC>NCT01244035</DOC>
	<brief_summary>This is a two part study comprising sequential double-dummy, placebo controlled 3-period randomized crossover studies. The study will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of different doses and dose regimens of MK-8266.</brief_summary>
	<brief_title>A Study of the Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008 AM1)(COMPLETED)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<criteria>Participant has essential hypertension who is in grade 1 or 2 hypertension according to the European Society of Hypertension (ESH) as delineated in the European Society of Cardiology (ESC) 2007 guidelines, i.e. systolic blood pressure values of 140179 and diastolic blood pressure values of 90109 on at least 3 occasions prior to the study. Otherwise healthy participants with grade 1 or 2 arterial hypertension who are treated with a single antihypertensive drug and meet the above blood pressure criteria may be enrolled at the discretion of the investigator Participant is generally in good health with the exception of hypertension Participant is a nonsmoker and/or has not used nicotine or nicotinecontaining products for 6 months Participant has a history of any illness that might confound the results of the study or pose and additional risk to the participant if they take part in the study Participant has a history of stroke, chronic seizures, or major neurological disorder Participant has a disability that can interfere with rising from a semirecumbent position to the standing position Participant has a personal or family history of a bleeding or clotting disorder Participant has a history of frequent nosebleeds or recurrent or active gingivitis Participant has a history of cancer, except 1) certain skin cancers; 2) cancer successfully treated more than 10 years prior to the study that has not recurred; or, 3) participants who are unlikely to have a recurrence during the study Participant has a history of cardiac disease including but not limited to heart valve disease or evidence of secondary cardiac damage Participant is categorized as class II or greater according to the New York Heart Association (NYHA) functional classification for heart failure Participant is unable to refrain from use of prescription or nonprescription drugs or herbal remedies (such as St. John's Wort) during the study Participant anticipates using phosphodiesterase (PDE5) inhibitors [sildenafil (Viagra®), tadalafil (Cialis®), or vardenafil (Levitra®)] during the study Participant consumes excessive amounts of alcohol (more than 3 drinks per day) or caffeine (more than 6 servings a day) Participant has had major surgery, donated or lost 1 unit of blood, or participated in another investigational within 4 weeks prior to the study Participant has a history of multiple and/or severe allergies, or has had an anaphylactic reaction or intolerance to any drugs or food</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>High blood pressure</keyword>
</DOC>